Extension of the CBYM338B2203 Phase IIb/III Study to Evaluate the Long-term Efficacy, Safety and Tolerability of Intravenous BYM338 in Patients With Sporadic Inclusion Body Myositis
Phase of Trial: Phase III
Latest Information Update: 04 Jul 2017
At a glance
- Drugs Bimagrumab (Primary)
- Indications Inclusion body myositis
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
- 28 Jun 2017 Status changed from active, no longer recruiting to completed.
- 03 May 2017 This trial has been completed in Netherlands (end date: 13 Feb 2017).
- 23 Mar 2017 This trial has been completed in Denmark (end date: 13 Feb 2017).